SGLT2 Inhibitors and GLP-1 Receptor Agonists in Cardiorenal-Metabolic Syndrome: Canadian Evidence, Mechanistic Complementarity, and Pharmacotherapeutic Strategies
International Journal of Clinical Pharmacy and Medicine · 01.07.2026 · 1 (1)
DOI: 10.68760/ijcpm.2026.07 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Clinical Pharmacy and Medicine, online erschienen am 01.07.2026. Verfasst von Mohamed Abdellatif.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Abdellatif, M. (2026). SGLT2 Inhibitors and GLP-1 Receptor Agonists in Cardiorenal-Metabolic Syndrome: Canadian Evidence, Mechanistic Complementarity, and Pharmacotherapeutic Strategies. International Journal of Clinical Pharmacy and Medicine, 1(1). https://doi.org/10.68760/ijcpm.2026.07
Vancouver
Abdellatif M. SGLT2 Inhibitors and GLP-1 Receptor Agonists in Cardiorenal-Metabolic Syndrome: Canadian Evidence, Mechanistic Complementarity, and Pharmacotherapeutic Strategies. International Journal of Clinical Pharmacy and Medicine. 2026;1(1). doi:10.68760/ijcpm.2026.07
BibTeX
@article{Abdellatif2026,
author = {Abdellatif, Mohamed},
title = {SGLT2 Inhibitors and GLP-1 Receptor Agonists in Cardiorenal-Metabolic Syndrome: Canadian Evidence, Mechanistic Complementarity, and Pharmacotherapeutic Strategies},
journal = {International Journal of Clinical Pharmacy and Medicine},
year = {2026},
volume = {1},
number = {1},
doi = {10.68760/ijcpm.2026.07}
}
EUVIMED